Cover Story
- Liquidity rush from major central banks has pushed markets into a high valuation zone. Why investors should tread cautiously as India gets into pandemic fatigue
Inside India's Vaccine Ecosystem
A blow-by-blow account of how Indian vaccines are being readied The world of vaccine and drug development is being reset. Here's how Indian pharma must reinvent to lead the new era of drug discovery and research
Gondal's Gastronomic Escapades
Ten trips to Japan in the last two years have made Gondal an ardent fan of Japanese cuisine, so much so that when Covid-19 cut short his travel plans, he indulged in cooking Japanese dishes at home Kedia joined a group of 8-10 like-minded musicians and singers, who were mostly into bhajans and Sufi. Since the pandemic happened, the group has been practicing every weekend over Zoom Agarwal, 56, has run five half marathons to date. "I recommend everyone to try running. Start very low and very slow - from there you will progress and achieve the unbelievable," he says
Remote Care
Hospitals, big and small, are increasingly taking to remote technologies for patient care. With the market expanding and vendors reinventing business models, are these technologies here to stay?
Reform Pangs
State laws may delay progress of Centre's agri-marketing reforms, but won't be able to halt them
Saving Taxes
You can save taxes either by investing in government-notified products or by claiming exemptions on certain type of expenses. The lowdown
Valuing LIC
How the 64-year-old Life Insurance Corporation should be valued for stock market listing
"We Are Building a Strategic Disinvestment Pipeline"
The pandemic had put the brakes on the government's ambitious disinvestment plans for the fiscal. However, things have started picking up as businesses go back to normal and markets regain their appetite for buying assets. DIPAM Secretary Tuhin Kanta Pandey lays down the road ahead for the department
Super Bowl
The cloud kitchen business takes off as the pandemic changes the food and beverages landscape
The Vaccine Sprint
In stark contrast to the mayhem around the world, India's top three candidates - Serum-Oxford, Bharat Biotech and Zydus Cadila continued their scientific pursuits unobtrusively (the fourth, DRL-Gamaleya, just started India trials). At least 16 more vaccines are under development at home
Looking for the Thump
Royal Enfield is inching towards the end of its purple patch at a time rivals have lined up new launches to take it head on. Can its new bike, Meteor 350, herald the start of another bull run?
